CLONIDINE HYDROCHLORIDE

Main information

  • Trade name:
  • CLONIDINE HYDROCHLORIDE- clonidine hydrochloride tablet
  • Composition:
  • CLONIDINE HYDROCHLORIDE 0.1 mg
  • Administration route:
  • ORAL
  • Prescription type:
  • PRESCRIPTION DRUG
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • CLONIDINE HYDROCHLORIDE- clonidine hydrochloride tablet
    United States
  • Language:
  • English

Therapeutic information

  • Therapeutic indications:
  • Clonidine hydrochloride tablets are indicated in the treatment of hypertension. Clonidine hydrochloride tablets may be employed alone or concomitantly with other antihypertensive agents. Clonidine hydrochloride tablets should not be used in patients with known hypersensitivity to clonidine (see PRECAUTIONS).
  • Product summary:
  • Clonidine Hydrochloride Tablets, USP are available containing 0.1 mg, 0.2 mg or 0.3 mg of clonidine hydrochloride, USP. The 0.1 mg tablets are white round scored tablets debossed with MYLAN above the score and 152 below the score on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-0152-01 bottles of 100 tablets NDC 0378-0152-10 bottles of 1000 tablets The 0.2 mg tablets are white round scored tablets debossed with MYLAN above the score and 186 below the score on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-0186-01 bottles of 100 tablets NDC 0378-0186-10 bottles of 1000 tablets The 0.3 mg tablets are white round scored tablets debossed with MYLAN above the score and 199 below the score on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-0199-01 bottles of 100 tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from light. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. REVISED JUNE 2012 CLON:R15

Status

  • Source:
  • DailyMed - NLM - National Library of Medicine
  • Authorization status:
  • Abbreviated New Drug Application
  • Authorization number:
  • 0378-0152-01, 0378-0152-10, 0378-0186-01, 0378-0186-10, 0378-0199-01
  • Last update:
  • 18-06-2019

Summary of Product characteristics: dosage, interactions, side effects

CLONIDINE HYDROCHLORIDE- clonidine hydrochloride tablet

Mylan Pharmaceuticals Inc.

----------

DESCRIPTION

Clonidine hydrochloride is a centrally acting alpha-agonist hypotensive agent available as tablets for

oral administration in three dosage strengths: 0.1 mg, 0.2 mg and 0.3 mg. The 0.1 mg tablet is equivalent

to 0.087 mg of the free base.

Clonidine hydrochloride is an imidazoline derivative and exists as a mesomeric compound. The

chemical name is 2-(2,6-dichlorophenylamino)-2- imidazoline hydrochloride. The following is the

structural formula:

C H C N HCl M.W. 266.56

Clonidine hydrochloride, USP is an odorless, bitter, white, crystalline substance soluble in water and

alcohol.

Each tablet for oral administration contains ammonium chloride, colloidal silicon dioxide,

croscarmellose sodium (Type A), magnesium stearate, microcrystalline cellulose, sodium lauryl

sulfate.

CLINICAL PHARMACOLOGY

Clonidine stimulates alpha-adrenoreceptors in the brain stem. This action results in reduced sympathetic

outflow from the central nervous system and in decreases in peripheral resistance, renal vascular

resistance, heart rate, and blood pressure. Clonidine hydrochloride tablets act relatively rapidly. The

patient's blood pressure declines within 30 to 60 minutes after an oral dose, the maximum decrease

occurring within 2 to 4 hours. Renal blood flow and glomerular filtration rate remain essentially

unchanged. Normal postural reflexes are intact; therefore, orthostatic symptoms are mild and infrequent.

Acute studies with clonidine hydrochloride in humans have demonstrated a moderate reduction (15% to

20%) of cardiac output in the supine position with no change in the peripheral resistance: at a 45° tilt

there is a smaller reduction in cardiac output and a decrease of peripheral resistance. During long-term

therapy, cardiac output tends to return to control values, while peripheral resistance remains decreased.

Slowing of the pulse rate has been observed in most patients given clonidine, but the drug does not alter

normal hemodynamic response to exercise.

Tolerance to the antihypertensive effect may develop in some patients, necessitating a reevaluation of

therapy.

Other studies in patients have provided evidence of a reduction in plasma renin activity and in the

excretion of aldosterone and catecholamines. The exact relationship of these pharmacologic actions to

the antihypertensive effect of clonidine has not been fully elucidated.

Clonidine acutely stimulates growth hormone release in both children and adults, but does not produce a

chronic elevation of growth hormone with long-term use.

Pharmacokinetics

9

9

l2

3

The pharmacokinetics of clonidine is dose proportional in the range of 100 mcg to 600 mcg. The

absolute bioavailability of clonidine on oral administration is 70% to 80%. Peak plasma clonidine levels

are attained in approximately 1 to 3 hours.

Following oral administration about 40% to 60% of the absorbed dose is recovered in the urine as

unchanged drug in 24 hours. About 50% of the absorbed dose is metabolized in the liver. Neither food

nor the race of the patient influences the pharmacokinetics of clonidine.

The antihypertensive effect is reached at plasma concentrations between about 0.2 and 2.0 ng/mL in

patients with normal excretory function. A further rise in the plasma levels will not enhance the

antihypertensive effect.

INDICATIONS AND USAGE

Clonidine hydrochloride tablets are indicated in the treatment of hypertension. Clonidine hydrochloride

tablets may be employed alone or concomitantly with other antihypertensive agents.

CONTRAINDICATIONS

Clonidine hydrochloride tablets should not be used in patients with known hypersensitivity to clonidine

(see PRECAUTIONS).

WARNINGS

Withdrawal

Patients should be instructed not to discontinue therapy without consulting their physician. Sudden

cessation of clonidine treatment has, in some cases, resulted in symptoms such as nervousness, agitation,

headache, and tremor accompanied or followed by a rapid rise in blood pressure and elevated

catecholamine concentrations in the plasma. The likelihood of such reactions to discontinuation of

clonidine therapy appears to be greater after administration of higher doses or continuation of

concomitant beta-blocker treatment and special caution is therefore advised in these situations. Rare

instances of hypertensive encephalopathy, cerebrovascular accidents and death have been reported after

clonidine withdrawal. When discontinuing therapy with clonidine hydrochloride tablets, the physician

should reduce the dose gradually over 2 to 4 days to avoid withdrawal symptomatology.

An excessive rise in blood pressure following discontinuation of clonidine hydrochloride tablet

therapy can be reversed by administration of oral clonidine hydrochloride or by intravenous

phentolamine. If therapy is to be discontinued in patients receiving a beta-blocker and clonidine

concurrently, the beta-blocker should be withdrawn several days before the gradual discontinuation of

clonidine hydrochloride tablets.

Because children commonly have gastrointestinal illnesses that lead to vomiting, they may be

particularly susceptible to hypertensive episodes resulting from abrupt inability to take

medication.

PRECAUTIONS

General

In patients who have developed localized contact sensitization to transdermal clonidine, continuation of

transdermal clonidine, or substitution of oral clonidine hydrochloride therapy may be associated with

the development of a generalized skin rash.

In patients who develop an allergic reaction to transdermal clonidine, substitution of oral clonidine

hydrochloride may also elicit an allergic reaction (including generalized rash, urticaria, or

hydrochloride may also elicit an allergic reaction (including generalized rash, urticaria, or

angioedema).

The sympatholytic action of clonidine may worsen sinus node dysfunction and atrioventricular (AV)

block, especially in patients taking other sympatholytic drugs. There are post-marketing reports of

patients with conduction abnormalities and/or taking other sympatholytic drugs who developed severe

bradycardia requiring IV atropine, IV isoproterenol and temporary cardiac pacing while taking

clonidine.

In hypertension caused by pheochromocytoma, no therapeutic effect of clonidine hydrochloride tablets

can be expected.

Perioperative Use

Administration of clonidine hydrochloride tablets should be continued to within 4 hours of surgery and

resumed as soon as possible thereafter. Blood pressure should be carefully monitored during surgery

and additional measures to control blood pressure should be available if required.

Information for Patients

Patients should be cautioned against interruption of clonidine hydrochloride tablet therapy without their

physician’s advice.

Since patients may experience a possible sedative effect, dizziness or accommodation disorder with use

of clonidine, caution patients about engaging in activities such as driving a vehicle or operating

appliances or machinery. Also, inform patients that this sedative effect may be increased by concomitant

use of alcohol, barbiturates or other sedating drugs.

Patients who wear contact lenses should be cautioned that treatment with clonidine hydrochloride tablets

may cause dryness of eyes.

Drug Interactions

Clonidine may potentiate the CNS-depressive effects of alcohol, barbiturates or other sedating drugs. If

a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the hypotensive

effect of clonidine may be reduced, necessitating an increase in the clonidine dose. If a patient

receiving clonidine is also taking neuroleptics, orthostatic regulation disturbances (e.g., orthostatic

hypotension, dizziness, fatigue) may be induced or exacerbated.

Monitor heart rate in patients receiving clonidine concomitantly with agents known to affect sinus node

function or AV nodal conduction, e.g., digitalis, calcium channel blockers and beta-blockers. Sinus

bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with

the use of clonidine concomitantly with diltiazem or verapamil.

Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats (see

Toxicology).

Based on observations in patients in a state of alcoholic delirium it has been suggested that high

intravenous doses of clonidine may increase the arrhythmogenic potential (QTprolongation, ventricular

fibrillation) of high intravenous doses of haloperidol. Causal relationship and relevance for clonidine

oral tablets have not been established.

Toxicology

In several studies with oral clonidine hydrochloride, a dose dependent increase in the incidence and

severity of spontaneous retinal degeneration was seen in albino rats treated for 6 months or longer.

Tissue distribution studies in dogs and monkeys showed a concentration of clonidine in the choroid.

In view of the retinal degeneration seen in rats, eye examinations were performed during clinical trials

in 908 patients before, and periodically after, the start of clonidine therapy. In 353 of these 908 patients,

the eye examinations were carried out over periods of 24 months or longer. Except for some dryness of

the eyes, no drug-related abnormal ophthalmological findings were recorded and, according to

specialized tests such as electroretinography and macular dazzle, retinal function was unchanged.

In combination with amitriptyline, clonidine hydrochloride administration led to the development of

corneal lesions in rats within 5 days.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Chronic dietary administration of clonidine was not carcinogenic to rats (132 weeks) or mice (78 weeks)

dosed, respectively, at up to 46 or 70 times the maximum recommended daily human dose as mg/kg (9 or

6 times the MRDHD on a mg/m basis). There was no evidence of genotoxicity in the Ames test for

mutagenicity or mouse micronucleus test for clastogenicity.

Fertility of male or female rats was unaffected by clonidine doses as high as 150 mcg/kg (approximately

3 times MRDHD). In a separate experiment, fertility of female rats appeared to be affected at dose

levels of 500 to 2000 mcg/kg (10 to 40 times the oral MRDHD on a mg/kg basis; 2 to 8 times the

MRDHD on a mg/m basis).

Usage in Pregnancy

Teratogenic Effects. Pregnancy Category C

Reproduction studies performed in rabbits at doses up to approximately 3 times the oral maximum

recommended daily human dose (MRDHD) of clonidine hydrochloride tablets produced no evidence of

a teratogenic or embryotoxic potential in rabbits. In rats, however, doses as low as 1/3 the oral MRDHD

(1/15 the MRDHD on a mg/m basis) of clonidine were associated with increased resorptions in a study

in which dams were treated continuously from 2 months prior to mating. Increased resorptions were not

associated with treatment at the same time or at higher dose levels (up to 3 times the oral MRDHD)

when the dams were treated on gestation days 6 to 15. Increases in resorption were observed at much

higher dose levels (40 times the oral MRDHD on a mg/kg basis; 4 to 8 times the MRDHD on a mg/m

basis) in mice and rats treated on gestation days 1 to 14 (lowest dose employed in the study was 500

mcg/kg).

No adequate, well controlled studies have been conducted in pregnant women. Clonidine crosses the

placental barrier (see CLINICAL PHARMACOLOGY: Pharmacokinetics). Because animal

reproduction studies are not always predictive of human response, this drug should be used during

pregnancy only if clearly needed.

Nursing Mothers

As clonidine hydrochloride is excreted in human milk, caution should be exercised when clonidine

hydrochloride tablets are administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established in adequate and well controlled

trials (see WARNINGS: Withdrawal).

ADVERSE REACTIONS

Most adverse effects are mild and tend to diminish with continued therapy. The most frequent (which

appear to be dose related) are dry mouth, occurring in about 40 of 100 patients; drowsiness, about 33 in

100; dizziness, about 16 in 100; constipation and sedation, each about 10 in 100.

The following less frequent adverse experiences have also been reported in patients receiving

clonidine hydrochloride tablets, but in many cases patients were receiving concomitant medication and

causal relationship has not been established.

Body as a Whole: Fatigue, fever, headache, pallor, weakness and withdrawal syndrome. Also reported

were a weakly positive Coombs’ test and increased sensitivity to alcohol.

Cardiovascular: Bradycardia, congestive heart failure, electrocardiographic abnormalities (i.e., sinus

node arrest, junctional bradycardia, high degree AV block and arrhythmias), orthostatic symptoms,

palpitations, Raynaud’s phenomenon, syncope and tachycardia. Cases of sinus bradycardia and

atrioventricular block have been reported, both with and without the use of concomitant digitalis.

Central Nervous System: Agitation, anxiety, delirium, delusional perception, hallucinations (including

visual and auditory), insomnia, mental depression, nervousness, other behavioral changes, paresthesia,

restlessness, sleep disorder, and vivid dreams or nightmares.

Dermatological: Alopecia, angioneurotic edema, hives, pruritus, rash and urticaria.

Gastrointestinal: Abdominal pain, anorexia, constipation, hepatitis, malaise, mild transient abnormalities

in liver function tests, nausea, parotitis, pseudo-obstruction (including colonic pseudo-obstruction),

salivary gland pain and vomiting.

Genitourinary: Decreased sexual activity, difficulty in micturition, erectile dysfunction, loss of libido,

nocturia and urinary retention.

Hematologic: Thrombocytopenia.

Metabolic: Gynecomastia, transient elevation of blood glucose or serum creatine phosphokinase and

weight gain.

Musculoskeletal: Leg cramps and muscle or joint pain.

Oro-otolaryngeal: Dryness of the nasal mucosa.

Ophthalmological: Accommodation disorder, blurred vision, burning of the eyes, decreased

lacrimation and dryness of eyes.

OVERDOSAGE

Hypertension may develop early and may be followed by hypotension, bradycardia, respiratory

depression, hypothermia, drowsiness, decreased or absent reflexes, weakness, irritability and miosis.

The frequency of CNS depression may be higher in children than adults. Large overdoses may result in

reversible cardiac conduction defects or dysrhythmias, apnea, coma and seizures. Signs and symptoms

of overdose generally occur within 30 minutes to 2 hours after exposure. As little as 0.1 mg of

clonidine has produced signs of toxicity in children.

There is no specific antidote for clonidine overdosage. Clonidine overdosage may result in the rapid

development of CNS depression; therefore, induction of vomiting with ipecac syrup is not

recommended. Gastric lavage may be indicated following recent and/or large ingestions. Administration

of activated charcoal and/or a cathartic may be beneficial. Supportive care may include atropine sulfate

for bradycardia, intravenous fluids and/or vasopressor agents for hypotension and vasodilators for

hypertension. Naloxone may be a useful adjunct for the management of clonidine-induced respiratory

depression, hypotension and/or coma; blood pressure should be monitored since the administration of

naloxone has occasionally resulted in paradoxical hypertension. Tolazoline administration has yielded

inconsistent results and is not recommended as first-line therapy. Dialysis is not likely to significantly

enhance the elimination of clonidine.

The largest overdose reported to date involved a 28-year old male who ingested 100 mg of clonidine

hydrochloride powder. This patient developed hypertension followed by hypotension, bradycardia,

apnea, hallucinations, semicoma, and premature ventricular contractions. The patient fully recovered

after intensive treatment. Plasma clonidine levels were 60 ng/mL after 1 hour, 190 ng/mL after 1.5

hours, 370 ng/mL after 2 hours, and 120 ng/mL after 5.5 and 6.5 hours. In mice and rats, the oral LD50

of clonidine is 206 and 465 mg/kg, respectively.

DOSAGE AND ADMINISTRATION

Adults

The dose of clonidine hydrochloride tablets must be adjusted according to the patient's individual blood

pressure response. The following is a general guide to its administration.

Initial Dose

0.1 mg tablet twice daily (morning and bedtime). Elderly patients may benefit from a lower initial dose.

Maintenance Dose

Further increments of 0.1 mg per day may be made at weekly intervals if necessary until the desired

response is achieved. Taking the larger portion of the oral daily dose at bedtime may minimize transient

adjustment effects of dry mouth and drowsiness. The therapeutic doses most commonly employed have

ranged from 0.2 mg to 0.6 mg per day given in divided doses. Studies have indicated that 2.4 mg is the

maximum effective daily dose, but doses as high as this have rarely been employed.

Renal Impairment

Patients with renal impairment may benefit from a lower initial dose. Patients should be carefully

monitored. Since only a minimal amount of clonidine is removed during routine hemodialysis, there is

no need to give supplemental clonidine following dialysis.

HOW SUPPLIED

Clonidine Hydrochloride Tablets, USP are available containing 0.1 mg, 0.2 mg or 0.3 mg of clonidine

hydrochloride, USP.

The 0.1 mg tablets are white round scored tablets debossed with MYLAN above the score and 152

below the score on one side of the tablet and blank on the other side. They are available as follows:

NDC 0378-0152-01

bottles of 100 tablets

NDC 0378-0152-10

bottles of 1000 tablets

The 0.2 mg tablets are white round scored tablets debossed with MYLAN above the score and 186

below the score on one side of the tablet and blank on the other side. They are available as follows:

NDC 0378-0186-01

bottles of 100 tablets

NDC 0378-0186-10

bottles of 1000 tablets

The 0.3 mg tablets are white round scored tablets debossed with MYLAN above the score and 199

below the score on one side of the tablet and blank on the other side. They are available as follows:

NDC 0378-0199-01

bottles of 100 tablets

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Protect from light.

Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

Mylan Pharmaceuticals Inc.

Morgantown, WV 26505 U.S.A.

REVISED JUNE 2012

CLON:R15

PRINCIPAL DISPLAY PANEL - 0.1 mg

NDC 0378-0152-01

Clonidine

Hydrochloride

Tablets, USP

0.1 mg

Rx only 100 Tablets

Each tablet contains 0.1 mg of

clonidine hydrochloride, USP.

Dispense in a tight, light-resistant

container as defined in the USP

using a child-resistant closure.

Keep container tightly closed.

Keep this and all medication

out of the reach of children.

Store at 20° to 25°C (68° to 77°F).

[See USP Controlled Room

Temperature.]

Protect from light.

Usual Adult Dosage: See accom-

panying prescribing information.

Mylan Pharmaceuticals Inc.

Morgantown, WV 26505 U.S.A.

Mylan.com

RM0152A8

PRINCIPAL DISPLAY PANEL - 0.2 mg

NDC 0378-0186-01

Clonidine

Hydrochloride

Tablets, USP

0.2 mg

Rx only 100 Tablets

Each tablet contains 0.2 mg of

clonidine hydrochloride, USP.

Dispense in a tight, light-resistant

container as defined in the USP

using a child-resistant closure.

Keep container tightly closed.

Keep this and all medication

out of the reach of children.

Store at 20° to 25°C (68° to 77°F).

[See USP Controlled Room

Temperature.]

Protect from light.

Usual Adult Dosage: See accom-

panying prescribing information.

Mylan Pharmaceuticals Inc.

Morgantown, WV 26505 U.S.A.

Mylan.com

RM0186A9

PRINCIPAL DISPLAY PANEL - 0.3 mg

NDC 0378-0199-01

Clonidine

Hydrochloride

Tablets, USP

0.3 mg

Rx only 100 Tablets

Each tablet contains 0.3 mg of

clonidine hydrochloride, USP.

Dispense in a tight, light-resistant

container as defined in the USP

using a child-resistant closure.

Keep container tightly closed.

Keep this and all medication

out of the reach of children.

Store at 20° to 25°C (68° to 77°F).

[See USP Controlled Room

Temperature.]

Protect from light.

Usual Adult Dosage: See accom-

panying prescribing information.

Mylan Pharmaceuticals Inc.

Morgantown, WV 26505 U.S.A.

Mylan.com

RM0199A9

CLONIDINE HYDROCHLORIDE

clonidine hydrochloride tablet

Product Information

Product T ype

HUMAN PRESCRIPTION DRUG

Ite m Code (Source )

NDC:0 378 -0 152

Route of Administration

ORAL

Active Ingredient/Active Moiety

Ingredient Name

Basis of Strength

Stre ng th

CLO NIDINE HYDRO CHLO RIDE (UNII: W76 I6 XXF0 6 ) (CLONIDINE -

UNII:MN3L5RMN0 2)

CLONIDINE

HYDROCHLORIDE

0 .1 mg

Inactive Ingredients

Ingredient Name

Stre ng th

AMMO NIUM CHLO RIDE (UNII: 0 1Q9 PC255D)

SILICO N DIO XIDE (UNII: ETJ7Z6 XBU4)

CRO SCARMELLO SE SO DIUM (UNII: M28 OL1HH48 )

MAGNESIUM STEARATE (UNII: 70 0 9 7M6 I30 )

MICRO CRYSTALLINE CELLULO SE (UNII: OP1R32D6 1U)

SO DIUM LAURYL SULFATE (UNII: 36 8 GB5141J)

Product Characteristics

Color

WHITE

S core

2 pieces

S hap e

ROUND

S iz e

6 mm

Flavor

Imprint Code

MYLAN;152

Contains

Packag ing

#

Item Code

Package Description

Marketing Start

Date

Marketing End

Date

1

NDC:0 378 -0 152-

10 0 in 1 BOTTLE, PLASTIC; Type 0 : No t a Co mbinatio n

Pro duc t

0 6 /0 9 /19 8 7

0 9 /30 /20 20

2

NDC:0 378 -0 152-

10 0 0 in 1 BOTTLE, PLASTIC; Type 0 : No t a Co mbinatio n

Pro duc t

0 6 /0 9 /19 8 7

0 9 /30 /20 20

Marketing Information

Marke ting Cate gory

Application Numbe r or Monograph Citation

Marke ting Start Date

Marke ting End Date

ANDA

ANDA0 70 317

0 6 /0 9 /19 8 7

0 9 /30 /20 20

CLONIDINE HYDROCHLORIDE

clonidine hydrochloride tablet

Product Information

Product T ype

HUMAN PRESCRIPTION DRUG

Ite m Code (Source )

NDC:0 378 -0 18 6

Route of Administration

ORAL

Active Ingredient/Active Moiety

Active Ingredient/Active Moiety

Ingredient Name

Basis of Strength

Stre ng th

CLO NIDINE HYDRO CHLO RIDE (UNII: W76 I6 XXF0 6 ) (CLONIDINE -

UNII:MN3L5RMN0 2)

CLONIDINE

HYDROCHLORIDE

0 .2 mg

Inactive Ingredients

Ingredient Name

Stre ng th

AMMO NIUM CHLO RIDE (UNII: 0 1Q9 PC255D)

SILICO N DIO XIDE (UNII: ETJ7Z6 XBU4)

CRO SCARMELLO SE SO DIUM (UNII: M28 OL1HH48 )

MAGNESIUM STEARATE (UNII: 70 0 9 7M6 I30 )

MICRO CRYSTALLINE CELLULO SE (UNII: OP1R32D6 1U)

SO DIUM LAURYL SULFATE (UNII: 36 8 GB5141J)

Product Characteristics

Color

WHITE

S core

2 pieces

S hap e

ROUND

S iz e

Flavor

Imprint Code

MYLAN;18 6

Contains

Packag ing

#

Item Code

Package Description

Marketing Start

Date

Marketing End

Date

1

NDC:0 378 -0 18 6 -

10 0 in 1 BOTTLE, PLASTIC; Type 0 : No t a Co mbinatio n

Pro duc t

0 6 /0 9 /19 8 7

0 9 /30 /20 20

2

NDC:0 378 -0 18 6 -

10 0 0 in 1 BOTTLE, PLASTIC; Type 0 : No t a Co mbinatio n

Pro duc t

0 6 /0 9 /19 8 7

0 9 /30 /20 20

Marketing Information

Marke ting Cate gory

Application Numbe r or Monograph Citation

Marke ting Start Date

Marke ting End Date

ANDA

ANDA0 70 317

0 6 /0 9 /19 8 7

0 9 /30 /20 20

CLONIDINE HYDROCHLORIDE

clonidine hydrochloride tablet

Product Information

Product T ype

HUMAN PRESCRIPTION DRUG

Ite m Code (Source )

NDC:0 378 -0 19 9

Route of Administration

ORAL

Active Ingredient/Active Moiety

Ingredient Name

Basis of Strength

Stre ng th

CLO NIDINE HYDRO CHLO RIDE (UNII: W76 I6 XXF0 6 ) (CLONIDINE -

UNII:MN3L5RMN0 2)

CLONIDINE

HYDROCHLORIDE

0 .3 mg

Mylan Pharmaceuticals Inc.

Inactive Ingredients

Ingredient Name

Stre ng th

AMMO NIUM CHLO RIDE (UNII: 0 1Q9 PC255D)

SILICO N DIO XIDE (UNII: ETJ7Z6 XBU4)

CRO SCARMELLO SE SO DIUM (UNII: M28 OL1HH48 )

MAGNESIUM STEARATE (UNII: 70 0 9 7M6 I30 )

MICRO CRYSTALLINE CELLULO SE (UNII: OP1R32D6 1U)

SO DIUM LAURYL SULFATE (UNII: 36 8 GB5141J)

Product Characteristics

Color

WHITE

S core

2 pieces

S hap e

ROUND

S iz e

8 mm

Flavor

Imprint Code

MYLAN;19 9

Contains

Packag ing

#

Item Code

Package Description

Marketing Start

Date

Marketing End

Date

1

NDC:0 378 -0 19 9 -

10 0 in 1 BOTTLE, PLASTIC; Type 0 : No t a Co mbinatio n

Pro duc t

0 6 /0 9 /19 8 7

0 9 /30 /20 20

Marketing Information

Marke ting Cate gory

Application Numbe r or Monograph Citation

Marke ting Start Date

Marke ting End Date

ANDA

ANDA0 70 317

0 6 /0 9 /19 8 7

0 9 /30 /20 20

Labeler -

Mylan Pharmaceuticals Inc. (059295980)

Revised: 6/2012